Wire · operational-macro
Bayer won FDA approval for first-in-class stroke drug Sunharbo
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 11 November 2026 · Fusion42 review
Bayer obtained FDA approval for Sunharbo (asundexian), the first-in-class factor XIa inhibitor to reduce stroke recurrence risk in certain adults, marking a new option in anticoagulant therapy for non-cardioembolic ischemic stroke and high-risk transient ischemic attack patients.
This Wire brief sits within Fusion42's coverage of Biotech, and 15 sources have reported it between 9 Nov 2026 and 19 Nov 2026.
◆ ◆ The Wire takeaway
You face a new market opening with Sunharbo providing a novel approach to stroke prevention that avoids cardioembolic cases. Stroke-focused neuro and biotech founders can shift attention to factor XIa inhibition as established players invest early in clinical uptake.
◆ Coverage
15 sources · first reported 9 Nov 2026 · latest 19 Nov 2026
◆ Related on Wire
◆ Topics